Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members — Chicago, Illinois, December 2020–March 2021

Teran, Richard; Walblay, Kelly; Shane, Elizabeth L.; Xydis, Shannon; Gretsch, Stephanie; Gagner, Alexandra; Samala, Usha; Choi, Hyeree; Zelinski, Christy; Black, Stéphanie

doi:10.1111/ajt.16634

Cited by 44 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several papers addressed the efficacy of different SARS-CoV-2 vaccines either through Phase II and III of clinical trials [ 21 – 23 ] or field investigations [ 9 – 11 ]. Few of them detailed data regarding elderly and persons living in LTCF [ 12 – 15 ] and outbreaks after the first and second dose were reported [ 24 – 26 ]. At present, cohorts <16 years or >80 years who might show reduced vaccine reactiveness are limited.…”

Section: Discussionmentioning

confidence: 99%

Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention

et al. 2022

View full text Add to dashboard Cite

Background The impact of coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on residents of long-term care facilities (LTCFs) has been dramatic on global scale as older age and comorbidities pose an increased risk of severe disease and death. Methods Aim of this study was to evaluate SARS-CoV-2 Spike-specific IgG (S-IgG) antibody titers in 478 residents and 649 health care workers of a large Italian long-term care facility two months after complete vaccination with BNT162b2. Associations among resident-related factors and predictors of humoral response were investigated. Results By stratifying levels of humoral responses, we found that 62.1%, 21.6%, 12.1% and 4.2% of residents had high (>1,000 BAU/ml), medium (101-1,000), low (1-100) and null (<1 BAU/mL) S-IgG titers, respectively. Residents with documented previous COVID-19 and those with SARS-CoV-2 nucleocapsid-specific IgG (N-IgG) positive serology showed higher level of serological response, while significant associations were observed for cancer with suboptimal response (p = 0.005) and the administration of corticosteroid for suboptimal response (p = 0.028) and a null one (p = 0.039). According to multivariate logistic regression, predictors of an increased risk of null response were advanced age (Odd ratio, OR: 2.630; Confidence interval, CI: 1.13-6.14; p = 0.025), corticosteroid therapy (OR: 4.964; CI: 1.06-23.52; p = 0.042) and diabetes mellitus (OR:3.415; CI:1.08-10.8; p = 0.037). In contrast, previous diagnosis of COVID-19 was strongly associated with a reduced risk of null response to vaccination (OR:0.126; CI:0.02-0.23; p < 0.001). Conclusions SARS-CoV-2 specific antibodies in elderly individuals should be consider when deciding the need of a third dose of vaccine for prevention of reinfections in LTCFs despite the maintenance of barrier measures.

show abstract

Section: Discussionmentioning

confidence: 99%

Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In fact, as of September 2021, our genomic surveillance data show that B.1.617.2 is dominant over B.1.1.7, indicating that a replacement is occurring (data not shown). The COVID-19 mRNA vaccines were shown to induce robust immune response and be effective against these circulating VOCs ( Liu et al, 2021b ; Choi et al, 2021 ; Hirotsu et al, 2021b ), however, it is important to continue the genomic surveillance and monitor trends for signs of an increase in the number of infected individuals ( Kustin et al, 2021 ) and breakthrough infection after vaccination ( Teran et al, 2021 ; Duerr et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1 lineage in Japan: Serial and stationary observation in a community

Hirotsu

Omata

2021

Infection, Genetics and Evolution

View full text Add to dashboard Cite

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulates in the world and acquires mutations during evolution. To identify the new emergent variants, the surveillance of the variants of concern (VOC) and variants of interest (VOI) is ongoing. This study aimed to determine how the transition of viral lineage occurred by stationary genome analysis in Yamanashi, Japan. Methods We performed the whole genome sequencing using SARS-CoV-2 positive samples collected from February 2020 to the end of June 2021. . Viral lineage was defined by the Phylogenetic Assignment of Named Global Outbreak (PANGO) lineages. Results We successfully obtained 325 viral genome sequences and the number of analyzed samples accounted for 15.4% of the total 2109 COVID-19 patients identified in our district. We identified 13 types of viral lineages including R.1, P.1, B.1.1.7 (Alpha) and B.1.617.2 (Delta) These virus lineages had distinct periods of expansion and decline. After the emerging of the R.1 lineage harboring E484K variant (designated VOI in Japan), the prevalent B.1.1.214 lineage were no longer identified. The R.1 lineages were temporarily prevalent afterwards, but the influx of B.1.1.7 lineage (designated VOC) led to a decline in R.1. Currently, B.1.1.7 has become dominant after mid-April 2021. Conclusion We clearly elucidated the transition and replacement of viral lineage by the community-based analysis. The virus completely replaced by more infectious lineages, therefore, it will be necessary to continue to monitor the VOC and VOI.

show abstract

“…Reports on vaccine breakthrough infections in vaccinated individuals are also accumulating, raising concern of developing escape mutants in the face of immune selection (26)(27)(28)(29)(30). A breakthrough infection is defined as a detection of SARS-CoV-2 antigen or RNA more than 14 days after receiving a COVID-19 vaccine.…”

Section: Spike Variants Pose a Threat To Current Vaccines And Therapeuticsmentioning

confidence: 99%

Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections

Ahmad

2021

Front. Immunol.

View full text Add to dashboard Cite

COVID-19 pandemic remains an on-going global health and economic threat that has amassed millions of deaths. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of this disease and is constantly under evolutionary pressures that drive the modification of its genome which may represent a threat to the efficacy of current COVID-19 vaccines available. This article highlights the pressures that facilitate the rise of new SARS-CoV-2 variants and the key mutations of the viral spike protein – L452R, E484K, N501Y and D614G– that promote immune escape mechanism and warrant a cautionary point for clinical and public health responses in terms of re-infection, vaccine breakthrough infection and therapeutic values.

show abstract

Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members — Chicago, Illinois, December 2020–March 2021

Cited by 44 publications

References 8 publications

Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention

Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention

SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1 lineage in Japan: Serial and stationary observation in a community

Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections

Contact Info

Product

Resources

About